Projects

The rapid emergence of new illegal drugs (HHC, nitazenes, synthetic cathinones, etc.) creates a need for fast, on-site drug testing tools that can detect multiple substances in biofluids. These tools are crucial for clinicians, anti-doping experts, and law enforcement. Multiplexed portable analytical tools have a great potential to be implemented for this purposes. Moreover, such kind of instruments could be utilized in personal healthcare monitoring by enabling early-stage diagnostics of health problems. This project aims to develop electrophoresis-based analytical tools for reliable, fast and cost-effective metabolism studies in vitro, revealing the characteristics and metabolic pathways of new psychoactive substances. Additionally, new on-site biofluid testing tools (focused on oral fluid) will be developed for detecting new drugs. The results of this project will enhance drug monitoring, support public health, and improve safety.

Antimicrobial resistance (AMR) and plastic pollution are global emergencies. Small microplastics (sMPs) (> 100µm) cause havoc in nature and are alarmingly prevalent in humans (e.g., placenta, brain, blood, and bone). sMPs also increase the risk of AMR by absorbing other pollutants (e.g., antibiotics) and promoting microbial aggregation and biofilm formation. Making screening and evaluation methods for new antibiofilm compounds widely available is essential. This project aims to develop a sustainable and democratized microfluidics platform to fight sMPs-induced AMR. Droplet-based microfluidics shows great potential for advancing knowledge and tackling this problem, allowing separation and manipulation of samples into thousands of miniscule drops (environments) for parallel studies. By using sustainable droplet technology with novel 3D-printed component for automated screening and evaluation of antibiofilm compounds, the project develops innovative solutions for global challenges.

The research infrastructure on experimental studies and applications of cellular processes aims at gathering national know-how in the field of cell and molecular biology, and aims at setting up an instrumental capability to develop competence and services in the fields of microbial and mammalian cell processes and their applications. The infrastructure will be built up jointly by the University of Tartu, Tallinn University of Technology, Tallinn University, Estonian University of Life Sciences and the Institute of Chemical Physics and Biophysics. The vision is to become a know-how and service centre to partner health, biotechnology and environment-focused public sector organisations, medical institutions, biotechnology and pharmacological companies. The focus will be on acquiring and setting up relevant instrumental complexes, development and offering of services, popularisation and dissemination of the field in order to ensure sustainability of researchers and future activities.

Reproduction is regulated by the endocrine system and its disturbances by endocrine disruptive chemicals (EDCs) may lead to infertility. As humans are constantly exposed to EDCs through the use of common household items and personal care products, it is important to test chemicals for their potential activity as endocrine disruptors affecting reproductive function. Project MERLON aims to study the effects of EDCs on sexual development and function in order to deliver new approach methodologies (NAMs) for EDC identification. While MERLON targets the vulnerable stages of development from fetal to puberty, MERLON2, with additional partner TalTech, will add one more sensitive window of susceptibility in female reproduction to the project: the adult preovulatory ovarian follicle, where the oocyte maturation takes place. In collaboration with TalTech, it was recently demonstrated that follicular somatic cells (FSCs) lose sensitivity to follicle stimulating hormone (FSH) in the presence of a mixture of 13 EDCs. FSH is crucial for both, the oocyte maturation and for the synthesis of steroid hormones by the FSCs. We have also demonstrated the intricate heterogeneity of somatic cells in the ovarian follicle. The roles that FSC subpopulations play in the adverse effects of EDCs is unknown and unaddressed by the initial MERLON project. MERLON2 will complement the aims of the consortium by developing NAMs based on single cell transcriptomics, automated image analysis and machine learning to understand the effect of EDCs on FSC subpopulations and their sensitivity to FSH. This will increase the research output for MERLON in the number of proposed NAMs and quantitative adverse outcome pathways. As a result of MERLON2 the range of stakeholders will enlarge, increasing the public awareness related to the harmful health effects of EDCs, and proposing new approaches to resolve the complicates issue of testing substances in everyday products for their adverse effects on human fertility.

Food and biotechnology industry needs new screening technologies to find cells with new properties (bacteria, yeasts, mammalian cells, etc) in order to produce high-value biomolecules (enzymes, antibodies, food components, etc). Those molecules are used in diagnostics, drug development of for making special foods. Droplet microfluidic-based screening technology is less resource-demanding alternative to traditional screening: cheaper because of less reagents used, faster due to small confined experimental volumes and machinery takes less lab space being table-top. Project CELLSIEVE will develop the technology in order to be used as a service-platform in collaboration with food and biomedicine industry.